Neutropenia occurs in up to 35% of babies admitted to the neonatal intensive care unit and is more likely in preterm infants, those with birth weights of less than 2000 g, and in multiple gestation pregnancies (1) . Neutropenia is also a particularly frequent finding in babies born to mothers with PIR, exposing them to an increased risk of sepsis (2) . The combination of neutropenia and sepsis results in a neonatal mortality rate of up to 60% (1) . Efforts have therefore been directed at the proportions of CFU-GM were (p < 0.05 and p < 0.001, respectively, compared with rhIL-3 alone). Fractional increases in CFU-G with rhG-CSF were independent of plasma concentraton of G-CSF (r = 0.17; 95% confidence interval -0.5 to 0.19; p = 0.35). rhG-CSF was more efficacious than rhGM-CSF in enhancing CFU-G numbers in rhIL-3-dependent cultures, and plasma conc entration of G-CSF did not predict response.
(Pediatr Res 37: 630-633, 1995) Abbreviations G-CSF, granuloc yte colony-stinrulating factor GM-CSF, granulocyt e-macrophage colony-stimulating factor rhG-CSF, recombinant human granulocyte colony-stimulating factor rhGM·CSF, recombinant human granulocyte-macrophage colony-stimulating factor [G-CSF], granulocyte colony-stimulating factor concentrations rhIL·3, recombinant human IL-3 CFU-G, granulocyte colony-forming unit CFU·GM, granulocyte-macrophage colony-forming unit PIH, pregnancy-induced hypertension IMDM, Iscove 's modification of Dulbecco 's medium enhancing neonatal neutrophil host defense. The hematopoietic growth factors G-CSF and GM-CSF have been used in the management of neutropenia secondary to various conditions (3). G-CSF acts on committed precursor cells to produce mature neutrophils, but may also have an effect on earlier progenitor cells when in combination with IL-3 (4, 5) . In animal models rhG-CSF has been shown to increase the circulating neutrophil number, neutrophil storage pool, and bone marrow progenitor pool and improve survival from group B Streptococcus infection when administered in combination with antibiotics (6, 7) . The former has also been shown for human neonates treated with rhG-CSF (8) . GM-CSF acts on multipotential, erythroid, and eosinophilic hematopoietic pro- Statistical analysis of colony culture data were by analysis of variance after log transformation to normalize the data; the least significant difference test was used to determine significant intergroup differences. The product-moment correlation coefficient was used to determine the relationship between endogenous [G-CSF] and fractional increase in colonies with addition of rhG-CSF to the culture system. (Fig. 2) . Although total CFU-G + CFU-GM were not increased in rhGM-CSF-supplemented cultures, the proportion of CFU-GM was (p < 0.05) ; CFU-GM were not increased with rhG-CSF supplementation (p > 0.05) (Fig. 3 ).
Comparing the actions of rhG-CSF and rhGM-CSF in IL-3-genitor cells and has activities overlapping with but distinct from IL-3 (9) (10) (11) . In clinical studies in adults rhGM-CSF given on an equal-mass basis does not increase neutrophil levels as much as rhG-CSF and results in a monocytosis and eosinophilia (3) . Given in combination with antibiotics to neonatal rats infected with group B streptococcus, rhGM-CSF has been shown to decrease mortality rates (12) . Thus both rhG-CSF and rhGM-CSF could potentially be used to enhance human neonatal neutrophil numbers and therefore augment neonatal host defense mechanisms. However , the comparative effects of rhG-CSF and rhGM-CSF on isolated human neonatal circulating progenitor cells has not previously been studied.
Neonates have an easily accessible, plentiful supply of circulating progenitor cells (13) , more abund ant than found in adults (14) . This study was designed primarily to quantitatively compare the effects of rhG-CSF and rhGM-CSF on human neonatal circulating progenitor cells, in an rhIL-3-dependent culture system and to establish which CSF would most effectively increase the number of neutrophilic cells, as measured by CFU-G production. Second, we aimed to investigate whether rhG-CSF and rhGM-CSF would affect progenitor cells from babies born to mothers with PIH, in a similar way to those from babies with normotensive mothers. Last we aimed to investigate whether or not the response to rhG-CSF correlated with endogenous plasma [G-CSF]. It has been proposed that neonatal neutropenia may be secondary to deficient production of endogenous G-CSF during activated states (15) . If this were the case we postulated that progenitor cells from neonates with low endogenous plasma [G-CSF] may be more responsive to exogenous rhG-CSF than cells from those with high endogenous plasma [G-CSF].
Patients and methods. Blood (0.5-1 mL) was collected from 25 newborn babies admitted to the regional tertiar y neonatal unit with the first routine blood sampling (at 0-2 h of life) into sterile tubes with preservative-free heparin (5 p,L containing 25 IV). Median gestational age was 32 wk (range 24-41 wk) and median birth weight was 1.70 kg (range 0.67-3.80 kg); three infants were born to mothers with PIH, diagnosed by previously defined criteria (2) . Further samples were obtained from three infants at 2 wk of age for repeat studies. Plasma was isolated after centrifugation (400 X g for 10 min) and stored at -20°C until [G-CSF] were estimated in duplicate using a commercial ELISA (British Biotechnology Products Ltd, Oxon OX14 3YS) . The cells were resuspended in IMDM (GIBCO , UK) (containing 102 U penicillin and 100 p,glmL streptomycin), supplemented with 10% heat-inactivated FCS (ICN Flow, UK), and centrifuged on Ficoll-Hypaque (400 X g for 25 min). The mononuclear fraction was isolated, washed twice in IMDM , and resuspended in IMDM with 10% FCS for counting. Progenitor cell responses to rhG-CSF and rhGM-CSF were assayed using a standard method. Briefly, 0.5 X 10 5 mononuclear cells were added to 1 mL IMDM in 35-mm dishes in duplicate supplemented with: 0.9% methylcellulose (Terry Fox Labs , Vancouver), 2 mM i-glutamine, 30% FCS, 1% BSA, 7.5 % NaHC0 3 , and 10-4 M p-mercaptoethanoI. Cell cultures from each infant were supplemented with the following combinations of recombinant growth factors , before incubating at 37°C in 5% CO 2 /95 % air: 50 ng/ml, rhIL-3 (sp act, BEDFORD RUSSELL ET AL. ... 
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fants born to mothers with PIH. These results are consistent with previous reports that rhG-CSF acts synergistically with rhIL-3 (5, 11). This effect was not seen with rhGM-CSF and is compatibl e with previous demonstrations that GM-CSF and IL-3 are not synergistic, but have overlapping activities at early stages of hematopoiesis (9) (10) (11) . This probably occurs because receptors for GM-CSF and IL-3 share a common (3-subunit resulting in binding cross-competition (17) .
We could not demonstrate synergism between rhG-CSF and rhGM-CSF in rhIL-3-dependent cultures. This is not surprising in view of the overlap in activities between IL-3 and GM-CSF. No colony growth occurred when available cells from newborn babies (n = 5) were cultured with rhG-CSF or rhGM-CSF in the absence of rhIL-3. Colony growth with the individual growth factors and synergy between rhG-CSF and rhGM-CSF in the absence of rhIL-3 has previously been demonstrated in preparations of highly enriched CD33+/ CD34+ cells from the bone marrow of normal adult volunteers (18) . However, this may be due to structural differences in preterm neonatal , compared with adult, stem cell receptors. Up-regulation of receptor expression may occur only after the early neonatal period, because temporal expression of the (3-subunit has been demonstrated in murine embryonic stem The individual responses of the infants born to mothers with PIH and the baby 's [G-CSF] and absolute neutrophil counts at the times of cell harvest are shown in Table 1 . Reference ranges for absolute neutrophil count are according to Manroe 's criteria at 0-2 h of age (16) . The progenitor cell responses of babies born to hypertensive and normotensi ve mothers were similar.
The response of progenitor cells to rhG-CSF, in terms of fractional increase in number of CFU-G, was independent of endogenous plasma [G-CSF] at the time of cell harvest (r = -0.17; 95% confidence interval -0.5 to 0.19; p = 0.35) (Fig. 4) .
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rhG-CSF, rhGM-CSF, AND NEONATAL GRANULOPOIESIS cells and early blastocysts (17, 19, 20) . Also significant differences have been found in lymphocyte phenotypes of human infants at birth and at 5 d of age (21) .
The clinical implication of our results is that if cytokine therapy is to be considered for the management of neonatal neutropenia rhG-CSF would be the most appropriate choice. This is consistent with the results of a clinic al study in older child ren with severe congenital neutropenia, in which rhG-CSF was more effective than rhGM-CSF at increasing neutrophil count (22) . lt is prob able that no benefit would be conferred by using rhG-CSF in combin ation with rhGM-CSF. Although only three infants born to mothers with PIH were studied, our results suggest that therapy with rhG-CSF is likely to be of benefit for such babies.
There have been few reported side effects of rhG-CSF therapy. In contrast, rhGM-CSF has been shown to have effects possibl y related to the secondary induction of proinfl.ammatory cytokines such as tumor necrosis factor-a and IL-6 (IL-6) (23, 24) . Monocytes and macrophages are a principle cellular source of tumor necrosis factor-a (25) , and increased local production of tumor necrosis factor-a may contribute to neonatal respiratory distress syndrome and its sequelae (26). The fact that monocyte progenitors (CFU-GM) were not increased by rhG-CSF in our study, but were by rhGM-CSF, suggests that rhG-CSF may be safer than rhGM-CSF in preterm neonates .
The lack of correlation between endogenous plasma [G-CSF] and in vitro response implies that in the clinical situation measur ement of plasma [G-CSF] will not usefully predict those babies who will respond to rhG-CSF therapy.
In summary the results of our study indicate that rhG-CSF, but not rhGM-CSF, enhances the rhIL-3-dependent proliferation of neonatal circulating progenitor cells to form greater number s of CFU-G . rhGM-CSF selectively increases the proportion of CFU-GM but not the overall colony number; and its actions are not synergistic with rhIL-3 or rhG-CSF in the presence of rhIL-3 .
Clinical trials in human neonates are warra nted to assess the potential use of rhG-CSF for reducing the morbidity and mortality associated with neutropenia, especially when sepsis supervenes.
